Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 53

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 53
---
 base salary of $463,500 and is eligible to receive an annual performance bonus with a target amount of 40% of his annual base salary, based on his achievement of Company performance goals (50%) related to clinical, pipeline development, and financing milestones and objectives, and individual performance goals (50%). Mr. Yonehiro is also eligible to receive potential termination or change in control payments pursuant to the Severance Plan, as described in “—Potential Payments upon Termination or Change in Control” below.

Consulting Agreements

In connection with the reduction-in-force In May 2024, we announced a strategic pipeline prioritization and restructuring plan, and Dr. Schatzman and Dr. Perez resigned as our chief executive officer and chief medical officer, respectively. In connection with such resignations, in order to ensure an orderly transition of duties, we entered into a consulting agreement with each of Dr. Schatzman and Dr. Perez. The key terms of these consulting agreements are described below.

Randall C. Schatzman, Ph.D.

In May 2024, Dr. Schatzman's resigned as our chief executive officer and remained an employee until July 15, 2024, at which time he became an advisor to the Company pursuant to a consulting agreement entered into on May 13, 2024 (the “Schatzman Consulting Agreement”). Pursuant to the Schatzman Consulting Agreement, we and Dr. Schatzman mutually agreed that commencing July 15, 2024 until the earlier of (i) nine months following July 15, 2024 or (ii) a termination in accordance with the terms of the Schatzman Consulting Agreement, Dr. Schatzman would provide certain advisory services to support us with the orderly transition of his duties. Pursuant to the Schatzman Consulting Agreement, a total of 1,248,571 stock options previously granted to Dr. Schatzman were canceled. The Schatzman Consulting Agreement terminated by its terms on April 15, 2025. Dr. Schatzman also received termination payments pursuant to the Severance and Change in Control Plan, or the Severance Plan, as described below in “—Potential Payments upon Termination or Change in Control”.

Edith A. Perez, M.D.

In May 2024, Dr. Perez's resigned as our chief medical officer and remained an employee until July 15, 2024, at which time she became an advisor to the Company pursuant to a consulting agreement entered into on